Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-06-17

Clinical Trial Update: A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008) [Phase 2]

View source ↗

Summary

Phase 2 study results evaluating the efficacy and safety of Vibegron (MK-4618) in adults with overactive bladder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Vibegron (vibegron)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Urinary Bladder, Overactive | Phase 2 | Status: COMPLETED | Results posted: 2016-06-17